<DOC>
	<DOCNO>NCT00933374</DOCNO>
	<brief_summary>This single arm open- label phase II- trial evaluate safety efficacy paclitaxel RAD001 patient metastatic urothelial bladder cancer fail prior platin-based systemic therapy .</brief_summary>
	<brief_title>Trial Evaluate Paclitaxel Plus RAD001 Urothelial Carcinoma</brief_title>
	<detailed_description>The screening phase check eligibility evaluation patient prior start study treatment last 21 days.Tumor histology must predominant urothelial carcinoma confirm histological cytological.Patients meet inclusion criterion treat paclitaxel 175 mg/m2 every 3 week RAD001 10 mg daily . Each cycle use combination paclitaxel 175 mg/m2 3-weekly RAD001 10 mg daily start day 1 21 day treatment cycle . Additional visit day 1 perform day 8 day 15 cycle Assessment safety toxicity perform every visit . Patients treat sign clinical radiological progression evident study treatment well tolerate maximum 6 cycle .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologically proven carcinoma urinary tract include urinary bladder , ureter , renal pelvis lower urinary tract . Urothelial carcinoma predominant histology Confirmation locally relapse metastatic disease imaging . Measurable disease accord RECIST guideline ≥1 measurable lesion evident . If bone metastatic site quantification target lesion ( ) use MRI mandatory . Failure prior platin base chemotherapy Patients may show progressive disease within first 3 month platinbased chemotherapy ( primary failure ) progression within 3 month end platinbased chemotherapy ( early relapse ) Prior therapy ≤ 4 chemotherapeutic drug Patients tumor relapse within 3 month cystectomy neoadjuvant adjuvant set eligible . ECOG performance status 02 Adequate haematological , liver renal function . Neutrophil count &gt; 1500/mm3 , haemoglobin &gt; 9 g/dl , platelet ≥ 100.000/ mm3 Serum bilirubin ≤ 1.5 x ULN , ALT AST ≤ 2.5x ULN . Patients know liver metastasis AST ALT ≤ 5x ULN . serum creatinine ≤ 2 x ULN . Women childbearing potential must negative serum urine pregnancy test within 14 day prior first dose study drug . Female subject childbearing potential must use two acceptable method contraception , time screen duration study , study completion 3 month follow study completion Age &gt; 18 year . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Patients must give write informed consent No concurrent treatment experimental drug anticancer drug Another distinguishable malignancy permit chemotherapy , radiation therapy anticancer therapy within 4 week first dose study drug . Participation clinical investigation within 4 week prior initial dosing . know hypersensitivity RAD001 rapamycin analog paclitaxel taxanes , excipients . previously receive RAD001 , mTOR inhibitor taxanes epothilones know metastasis central nervous system . symptomatic pleural effusion symptomatic ascites . wide field radiation therapy ≥ 25 % bone marrow within 4 week prior therapy . intravenous radionuclide therapy , e.g . phosphorus ( 32P ) , strontium ( 89SrCl ) , rhenium ( 186Re ) samarium ( 153Sm ) . Patients undergone major surgery within 4 week prior start study drug , open biopsy , significant traumatic injury , recover side effect . Chronic systemic treatment corticosteroid correspond prednisone equivalent &gt; 10 mg daily . Patients receive corticosteroid must stable dose ≥ 4 week prior first dose RAD001 . Topical inhale corticosteroid permit . Concomitant medication strong CYP3A4 inhibitor CYP3A4 inducer . active bleeding diathesis . Neuropathy &gt; grade 1. severe and/or uncontrolled medical condition ( unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month , serious uncontrolled cardiac arrhythmia , uncontrolled hyperlipidemia , active uncontrolled severe infection , cirrhosis , chronic persistent active hepatitis ) severely impaired lung function define spirometry DLCO 50 % normal predict value and/or O2 saturation ≤ 88 % rest room air Uncontrolled diabetes Hepatic impairment ChildPugh score &gt; 9</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>RAD001</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>